Activity of epothilones

Current Opinion in Investigational Drugs

Volumn 6, Issue 6, 2005, Pages 616-622

  Kolman, Ada ^a  

^a STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

Apoptosis; Cancer; Epothilones; Human tumor xenografts; Microtubules; Multidrug resistance; Paclitaxel; Tumor cell lines

Indexed keywords

ANTINEOPLASTIC AGENT; BMS 310705; DOXORUBICIN; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; IXABEPILONE; PACLITAXEL; TUBULIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; BIOLOGICAL ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL DEATH; CELL DIVISION; CELL STRAIN MCF 7; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL TRIAL; DRUG HALF LIFE; DRUG SCREENING; DRUG STRUCTURE; GENE EXPRESSION REGULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN BINDING; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SYSTEMATIC REVIEW; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CLINICAL TRIALS; EPOTHILONES; GENE EXPRESSION; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS;

EID: 20744453851     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CA: Epothilones, a new class of microtubule-stabilizing agents with taxol-like mechanism of action. Cancer Res (1995) 55(11):2325-2333.
2. Gerth K, Bedorf N, Höfle G, Irschik H, Reichenbach H: Epothilones A and B: Antifungal and cytotoxic compounds from Sorangium cellulosum (myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) (1996) 49(6):560-563.
3. Hardt IH, Steinmetz H, Gerth K, Sasse F, Reichenbach H, Höfle G: New natural epothilones from Sorangium cellulosum, strains So ce90/B2 and So ce90/D13: Isolation, structure elucidation, and SAR studies. J Nat Prod (2001) 64(7):847-856.
4. Nicolaou KC, Ritzén A, Namoto K: Recent developments in the chemistry, biology and medicine of the epothilones. Chem Commun (Camb) (2001) 7(17):1523-1535.
5. Rowinsky EK, Cazenave LA, Donehower RC: Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst (1990) 82(15):1247-1259.
6. Rowinsky EK: The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med (1997) 48:353-374.
7. Chou TC, Zhang X-G, Balog A, Su D-S, Meng D, Savin K, Bertino JR, Danishefsky SJ: Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci USA (1998) 95(16):9642-9647.
8. Chou TC, O'Connor OA, Tong WP, Guan Y, Zhang ZG, Stachel SJ, Lee C, Danishefsky SJ: The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc Natl Acad Sci (2001) 98(14):8113-8118.
9. Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA: BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res (2001) 7(5):1429-1437.
10. Lee FY, Vite G, Höfle G, Kim SH, Clark J, Fager K, Kennedy K, Smykla R, Wen ML, Leavitt K, Johnston K et al: The discovery of BMS-310705: A water-soluble and chemically stable semi-synthetic epothilone possessing potent parenteral and oral antitumor activity against models of taxane-sensitive and -resistant human tumors in vivo. Proc Am Assoc Cancer Res (2002) 43:Abs 3928.
11. Vite G, Höfle G, Bifano M, Fairchild C, Glaser N, Johnston K, Kamath A, Kim SH, Leavitt K, Lee FY, Leibold T et al: The semisynthesis and preclinical evaluation of BMS-310705, an epothilone analog in clinical development. Am Chem Soc (2002) 223:Abs MEDI 18.
12. Kolman A: BMS-310705 Bristol-Myers Squibb/GBF. Curr Opin Investig Drugs (2004) 5(12):1292-1297.
13. Tang L, Shah S, Chung L, Carney J, Katz L, Khosla C, Julien B: Cloning and heterologous expression of the epothilone gene cluster. Science (2000) 287(5453):640-642.
14. Julien B, Shah S, Ziermann R, Goldman R, Katz L, Khosla C: Isolation and characterization of the epothilone biosynthetic gene cluster from Sorangium cellulosum. Gene (2000) 249(1-2):153-160.
15. Nagano S, Li H, Shimizu H, Nishida C, Ogura H, Ortiz de Montellano PR, Poulos TL: Crystal structures of epothilone D-bound, epothilone B-bound and substrate-free forms of cytochrome P450epoK. J Biol Chem (2003) 278(45):44886-44893.
16. Julien B, Shah S: Heterologous expression of epothilone biosynthetic genes in Myxococcus xanthus. Antimicrob Agents Chemother (2002) 46(9):2772-2778.
17. Kowalski RJ, Giannakakou P, Hamel E: Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol). J Biol Chem (1997) 272(4):2534-2541.
18. Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC, Fojo T: A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA (2000) 97(6):2904-2909.
19. Ojima I, Chakravarty S, Inoue T, Lin S, He L, Horwitz SB, Kuduk SD, Danishefsky S: A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc Natl Acad Sci USA (1999) 96(8):4256-4261.
20. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH: The binding mode of epothilone A on α,β-tubulin by electron crystallography. Science (2004) 305(5685):866-869.
21. White JD, Carter RG, Sundermann KF, Wartmann M: Total synthesis of epothilone B, epothilone D, and cis- and trans-9,10-dehydroepothilone D. J Am Chem Soc (2001) 123(23):5407-5413.
22. Kamath K, Jordan MA: Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. Cancer Res (2003) 63(18):6026-6031.
23. Borst P, Evers R, Kool M, Wijnholds J: A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst (2000) 92(16):1295-1302.
24. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer (2002) 2(1):48-58.
25. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS: Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem (1997) 272(27):17118-17125.
26. Chen JG, Yang C-P, Cammer M, Horwitz SB: Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res (2003) 63(15):7891-7899.
27. Khabele D, Lopez-Jones M, Yang WC, Arango D, Gross SJ, Augenlicht LH, Goldberg GL: Tumor necrosis factor-α related gene response to epothilone B in ovarian cancer. Gynecol Oncol (2004) 93(1):19-26.
28. Altmann KH, Wartmann M, O'Reilly T: Epothilones and related structures - a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta (2000) 1470(3):M79-M91.
29. Chou TC, Zhang X-G, Harris CR, Kuduk SD, Balog A, Savin KA, Bertino JR, Danishefsky SJ: Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci USA (1998) 95(26):15798-15802.
30. Kolman A: Epothilone D (Kosan/Roche). Curr Opin Investig Drugs (2004) 5(6):657-667.
31. Johnson RG, Carney J, Zhong Z, Cropp G, Sherrill M: Oral bioavailability of KOS-862 (epothilone D), a potent stabilizer of microtubulin polymerization in rats and beagle dogs. Proc Annu Meet Am Assoc Cancer Res (2003) 44:Abs 5339.
32. Wang H, Wang S, Wang Z, Li M, Nan L, Tomaszewski JE, Rhie JK, Zhang R, Hill DL: Pre-clinical in vitro and in vivo studies of epothilone D. A novel tubulin stabilizing anti-cancer agent. Clin Cancer Res (2001) 7(38):10S.
33. Lin N, Brakora K, Seiden M: BMS-247550 (Bristol-Myers Squibb/GBF). Curr Opin Investig Drugs (2003) 4(6):746-756.
34. Schimmer AD, Hadley DW, Penn LZ, Minden MD: Receptor- and mitochondrial-mediated apoptosis in acute leukemia: A translational view. Blood (2001) 98(13):3541-3553.
35. Uyar D, Takigawa N, Mekhail T, Grabowski D, Markman M, Lee F, Canetta R, Peck R, Bukowski R, Ganapathi R: Apoptotic pathways of epothilone BMS 310705. Gynecol Oncol (2003) 91(1):173-178.
36. Blagosklonny MV, Giannakakou P, El-Deiry WS, Kingston DG, Higgs PI, Neckers L, Fojo T: Raf-1/Bcl-2 phosphorylation: A step from microtubule damage to cell death. Cancer Res (1997) 57(1):130-135.
37. Kavallaris M, Verills NM, Hill BT: Anticancer therapy with novel tubulin-interacting drugs. Drug Resist Updates (2001) 4(6):392-401.
38. Borzilleri RM, Vite GD: Epothilones: New tubulin polymerization agents in preclinical and clinical development. Drugs Future (2002) 27(12):1149-1163.
39. Goodin S, Kane MP, Rubin EH: Epothilones: Mechanism of action and biological activity. J Clin Oncol (2004) 22(10):2015-2025.
40. Mani S, Macapinlac M Jr, Goel S, Verdier-Pinard D, Fojo T, Rothenberg M, Colevas D: The clinical development of new mitotic inhibitors that stabilize the microtubule. Anticancer Drugs (2004) 15(6):553-558.
41. Rothermel J, Wartmann M, Chen T, Hohneker J: EP0906 (epothilone B): A promising novel microtubule stabilizer. Semin Oncol (2003) 30(3 Suppl 6):51-55.
42. McDaid HM, Mani S, Shen HJ, Muggia F, Sonnichsen D, Horwitz SB: Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res (2002) 8(7):2035-2043.
43. Piro LD, Rosen LS, Parson M, Cropp GF, McDaid H, Han J, Matela J, Johnson RG, Hannah AL: KOS-862 (epothilone D): A comparison of two schedules in patients with advanced malignancies. Proc Am Soc Clin Oncol (2003) 22:Abs 539.
44. Mani S, McDaid H, Hamilton A, Hochster H, Cohen MB, Khabelle D, Griffin T, Lebwohl DE, Liebes L, Muggia F, Horwitz SB: Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res (2004) 10(4):1289-1298.
45. Rubin EH, Siu LL, Beers S, Moore MJ, Thompson C, Becker M, Chen TL, Cohen P, Rothermel J, Oza AM: A phase I and pharmacologic trial of weekly epothilone B in patients with advanced malignancies. Proc Am Soc Clin Oncol (2001) 20:Abs 270.
46. Awada A, Bleiberg H, de Valeriola D, Huart A, Comez N, Letrent S, Martin C, Piccart M: Phase I clinical and pharmacology study of the epothilone analog BMS-247550 given weekly in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol (2001) 20:Abs 427.
47. Spriggs D, Soignet S, Bienvenu B, Letrent S, Lebwohl D, Jones S, Burris H III: Phase I first-in-man study of the epothilone B analog BMS-247550 in patients with advanced cancer. Proc Am Soc Clin Oncol (2001) 20:Abs 428.
48. Hao D, Hammond LA, deBono JS, Tolcher AW, Berg KE, Bass A, Mays TA, Smith LS, Drengler R, Rowinsky EK: Continuous weekly administration of the epothilone-B derivative, BMS247550 (NSC710428): A phase I and pharmacokinetic (PK) study. Proc Am Soc Clin Oncol (2002) 21:Abs 411.
49. Ajani JA, Shah MA, Bokemeyer C, Lenz HJ, Burris HA, Van Cutsem E, Usakewicz J, Peeters O, Voi M, Lebwohl D, Safran H: Phase II study of the novel epothilone BMS-247550 in patients (pts) with metastatic gastric adenocarcinoma previously treated with a taxane. Proc Am Soc Clin Oncol (2002) 21:Abs 619.
50. Thomas E, Tabernero J, Fornier M, Fumoleau P, Lluch A, Viens P, Vahdat L, Conte P, Peck R, Martin M: A phase II study of the epothilone B analog BMS-247550 in patients (pts) with taxane-resistant metastatic breast cancer. Proc Am Soc Clin Oncol (2003) 22:Abs 30.
51. Roche HH, Cure H, Bunnell C, Cognetti F, Mauriac F, Perez E, Miller K, Sparano J, Peck R, Yelle L: A phase II study of epothilone analog BMS-247550 in patients (pts) with metastatic breast cancer (MBC) previously treated with anthracycline. Proc Am Soc Clin Oncol (2003) 22:Abs 69.
52. Vansteenkiste JF, Breton JL, Sandler A, Lara P, Paz-Arez L, Bonomi P, Le Chevalier T, Ardizzoni A, Peck R, Edelman M: A randomized phase II study of epothilone analog BMS-247550 in patients (pts) with non-small cell lung cancer (NSCLC) who have failed first-line platinum-based chemotherapy. Proc Am Soc Clin Oncol (2003) 22:Abs 2519.
53. Eng C, Kindler HL, Skoog L, Ansari RH, Nattam S, Kasza K, Wade-Oliver KT, Vokes EE: The epothilone analogue, BMS-247550, in patients (pts) with advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol (2003) 22:Abs 1134.
54. Smaletz O, Galsky M, Scher HI, DeLaCruz A, Slovin SF, Morris MJ, Solit DB, Davar U, Schwartz L, Kelly WK: Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann Oncol (2003) 14(10):1518-1524.
55. Bristol Myers Squibb Co: Mid-year financial report. Company World Wide Web Site (2003) August 18. http://www.bms.com/investors/financial
56. Mekhail T, Holden S, Pierson S, Lee F, Galbraith S, Cohen M, Messina M, Roedig B, Williams K, Weiss P, Persky M et al: A phase I pharmacokinetic and biologic study of the novel epothilone BMS-310705 in patients with advanced cancer. Proc Am Soc Clin Oncol (2002) 21:Abs 408.
57. Sessa C, Perotti A, Malossi A, Capri G, Cresta S, De Braud F, Dall'o E, Voi M, Marsoni S, Gianni L: Phase I and pharmacokinetic (PK) study of the novel epothilone BMS-310705 in patients (pts) with advanced solid cancer. Proc Am Soc Clin Oncol (2003) 22:Abs 519.
58. Calvert PM, O'Neill V, Twelves C, Azzabi A, Hughes A, Bale C, Robinson A, Machan M, Dimitrijevic S, Moss D, Rothermel J et al: A phase I clinical and pharmacokinetic study of EPO906 (epothilone B), given every three weeks, in patients with advanced solid tumors. Proc Am Soc Clin Oncol (2001) 20:Abs 429.
59. Aisner J, Gore M, Rubin EH, Wojtowicz M, Fessele K, Smith S, Chitale K, Yap A, Rothermel J, Kaye S: Two phase IB trials of EPO906 plus carboplatin in patients with advanced malignancies. Proc Am Soc Clin Oncol (2003) 22:Abs 574.
60. Poplin E, Moore M, O'Dwyer P, Clarke S, Hill M, Sessa C, Rothermel J, Mull R, Miller J, Rosen L: Safety and efficacy of EPO906 in patients with advanced colorectal cancer: A review of 2 phase II trials. Proc Am Soc Clin Oncol (2003) 22:Abs 1135.
61. Thompson JA, Swerdloff J, Escudier B, Dutcher JP, Bukowski RM, Vaishampayan U, Hussein A, Negrier S, Rothermel J: Phase II trial evaluating the safety and efficacy of EPO906 in patients with advanced renal cancer. Proc Am Soc Clin Oncol (2003) 22:Abs 1628.
62. Rosen PJ, Rosen LS, Britten C, Parson M, Cropp GF, McDaid H, Han J, Johnson RG, Hannah AL: KOS-862 (epothilone D): Results of a phase I dose-escalating trial in patients with advanced malignancies. Proc Am Soc Clin Oncol (2002) 21:Abs 413.
63. Kosan Biosciences Inc: Kosan and Roche's anticancer drug enters phase II trials. Press Release (2003) December 09.
64. Kosan Biosciences Inc: Roche and Kosan announce indication changes for KOS-862 phase II trials. Press Release (2004) June 22.
65. Kosan Biosciences Inc: Kosan NSCLC phase II trial discontinued. Press Release (2004) November 23.
66. Bristol-Myers Squibb Co (Lee FYL): Oral administration of epothilones. WO-03084536 (2003).